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Background: The aim of this study was to assess the management of cervical necrosis (CN) following radiotherapy
(RT) and the impact of smoking status. This rare complication mimics a neoplastic recurrence, and causes concern
among attending physicians.
Methods: Between July 2008 and March 2013, 5 women on 285 with localized cervical cancer had a CN following
RT. Patients were treated with concomitant chemoradiation. The medical records were reviewed to abstract
demographic and clinical information until March 2013.
Results: 1.75% (95% confidence interval: 0.23 to 3.28%) developed CN. All patients were smokers with a mean of
19.5 pack-years (range: 7.5-45 pack-years). All patients were treated with weekly Cisplatin chemotherapy and
external beam radiation to the pelvis, 45 Gy in 25 fractions. Four patients received an extra boost with a median
dose of 7.2 Gy (range: 5.4-10 Gy). All patients had intracavitary brachytherapy (range: 27.9 to 30 Gy). Clinical
presentation was similar for all the cases: vaginal discharge associated with pain. Mean time for time post-radiation
therapy to necrosis was 9.3 months (range: 2.2-20.5 months). Standard workup was done to exclude cancer
recurrence: biopsies and radiologic imaging. Conservative treatment was performed with excellent results.
Resolution of the necrosis was complete after a few months (range: 1 to 4 months). Median follow-up until March
2013 was 19 months. All the patients were alive with no clinical evidence of disease.
Conclusions: This study, the largest to date, shows that conservative management of CN after RT is effective, and
should be attempted. This complication is more common in smokers, and counseling intervention should result in
fewer complications of CN.
Keywords: Cervical cancer, Necrosis, Radiotherapy, Radiation therapy, Chemoradiation, Smoking, ManagementBackground
Chemoradiation, where platinum-based chemotherapy
is given concomitantly with radiotherapy, is considered
to be the standard of care for the treatment of locally
advanced cervical cancer since the clinical announce-
ment of the National Cancer Institute (NCI) in 1999.
Mild and acute side effects are experienced by most
patients, and are generally transitory [1-3]. Severe
long-term toxicity, accounting for 1% to 3% [4], is well
documented [5,6], and involves gastrointestinal and
urological systems: distal ureteral necrosis, distal ur-
eteral stenosis, vesico-vaginal fistula, vesico-intestinal* Correspondence: tvnh58@gmail.com
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reproduction in any medium, provided the orfistula, severe fibrotic bladder shrinkage, urethral sten-
osis, and bladder necrosis [7,8].
Cervical necrosis (CN) associated with radiation therapy
(RT) for cervical cancer has also been described. Since
1986, 5 case reports, the largest of which consisted of 3 pa-
tients, have been published in further support of CN fol-
lowing RT for a total of only 12 cases described in the
literature [9-13]. Interest in this field comes from more
than half a century ago with a case report on uterine ne-
crosis following irradiation for cervical carcinoma [14].
However, radiation therapy treatment has changed since
then, and limited information in the oncologic literature is
available for the clinicians on the management of this
complication, with most of the studies suggesting laparo-
scopic examination and surgical intervention.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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experienced that complication, the late toxic reaction of
cervical necrosis is described with an emphasis on the
clinical course and conservative management of this tox-
icity. This rare complication mimics a neoplastic recur-
rence, and causes concern among attending physicians.
Methods
Between July 2008 and March 2013, five women had a cer-
vical necrosis following radiation therapy for a localized
cervical cancer, which includes confined cancers with
stages up to IIIB. During this period, 285 patients with lo-
calized cervical cancer were treated with concomitant
chemoradiotherapy at the Department of Radiation On-
cology of the Notre-Dame Hospital of the University of
Montreal Hospital Center (Montreal, Canada). The medical
records of the patients were then reviewed, and analyzed to
abstract demographic and clinical information through the
oncological data archiving system at our center.
Following a careful and thorough history taking and
physical examination with investigation and biopsy, the
diagnosis for cervical cancer was made. Patients were
treated with concurrent chemoradiation with weekly
Cisplatin at a dose of 40 mg/m2 for radiosensitisation.
Our standard protocol in our centre consisted of exter-
nal beam radiotherapy (EBRT) to the whole pelvis. Pa-
tients with involved para-aortic nodes on imaging were
treated using an extended field technique. For pelvic or
para-aortic nodal involvement, a boost was added.
Intracavitary brachytherapy consisted of high-dose rate
(HDR) brachytherapy and was usually started during
EBRT. The procedure was performed by one of three
trained radiation oncologists at our center, and by a radi-
ation oncologist from another center for one patient. A
prescription was then given to the patients: vaginal topical
emollients for moisturizing, twice-weekly estradiol vaginal
tablets, and using a vaginal dilator every day, except when
there is sexual intercourse, to prevent and reverse the va-
ginal shrinkage. Patients were then followed alternately by
the gynecologic oncologist and the radiation oncologist
every 3 to 4 months in the first 2 to 3 years, and then
every 6 months up to 5 years, and thereafter annually
indefinitely. A follow-up positron emission tomography
(PET) scan was done 4 to 6 months after the radiotherapy.
At presentation with clinical features of the necrosis,
the clinical presentation was noted, as well as the date of
diagnosis for the necrosis. The time post-radiation ther-
apy before the necrosis was calculated in months. A cer-
vical biopsy was done for each patient, as well as
imaging by magnetic resonance imaging (MRI) or PET
scan to rule out a recurrence of the cancer. Management
and treatment of this complication were done, and pa-
tients were followed-up thereafter. Post-treatment clin-
ical improvement, smoking cessation after counselingand post-coital bleeding were also evaluated. The last
follow-up for all 5 patients was in March 2013.
In brief, the following parameters were analyzed: age at
diagnosis, stage, initial tumor size in centimeters, history
of abdominal surgery, smoking status, chemotherapy re-
ceived, radiation therapy delivered to the pelvis, boost to
lymph nodes, brachytherapy, date of last treatment, clin-
ical presentation, date of diagnosis for the necrosis, time
post-radiotherapy before necrosis in months, cervical bi-
opsy with the results, imaging with MRI or PET scan,
treatment of the necrosis, time to clinical improvement of
the necrosis after the treatment in months, smoking cessa-
tion or not after counseling, post-coital bleeding after the
necrosis, time of follow-up in months, and status in
March 2013.
Results
The characteristics for the parameters of the 5 cases in-
cluded in the study are shown in Table 1. Of the 285
women treated during this period, 5 (1.75%, 95% con-
fidence interval: 0.23 to 3.28%) developed CN after
chemoradiation for cervical carcinoma. Mean age at diag-
nosis of the CN was 36.4 years old (range: 28–49), while
mean age among the 285 patients was 51.45 years old (95%
confidence interval: 49.97 to 52.92 years old). The patients
had cancer stages ranging from IB-2 to IIIB with a mean
initial tumor size of 5.3 cm (range: 2.8-8.5), compared to
5.36 cm (95% confidence interval: 5.11 to 5.60 cm) for all
the patients treated during that period. None had a history
of abdominal surgery. Active smoking was found in 181 of
the 285 patients, representing 63.51% (95% confidence
interval: 57.92 to 69.10%). Of the 181 smokers, five have
developed the CN, representing 2.76% (95% confidence
interval: 0.37 to 5.15%). All patients with CN were smokers
with a mean of 19.5 pack-years (range: 7.5-45). All patients
were treated with weekly Cisplatin chemotherapy (4 re-
ceived 6 cycles; 1 received 7 cycles). The dose for external
beam radiation to the pelvis was the same for the 5 pa-
tients, 45 Gy in 25 fractions. 4 patients received an extra
boost of radiation to involved lymph nodes with a median
dose of 7.2 Gy (range: 5.4-10 Gy), and 1 patient did not get
an extra boost because she had no lymph node involve-
ment. All patients had intracavitary brachytherapy for
doses ranging from 27.9 to 30 Gy in 4 or 5 treatments.
Table 2 shows the brachytherapy dosimetry details with the
surface doses to the colpostats.
Clinical presentation was similar for all the patients: va-
ginal discharge associated with pelvic or abdominal pain
for at least 1 week before consultation. Vaginal bleeding
was also seen in two patients. Time post-radiation therapy
to necrosis was calculated, and the mean time was
9.3 months (range: 2.2-20.5). Cervical biopsy was done for
every patient. The results were similar, and correlate with
post-radiotherapy changes: necroinflammatory exudate
Table 1 Characteristics of patients with cervical necrosis following radiation therapy for cervical cancer
Characteristics 1 2 3 4 5
Age at diagnosis 28 36 35 49 34
Stage IB-2 IB-2 IIB IIB IIIB
Initial tumor size (cm) 8.5 5.6 3.9 2.8 5.6
History of surgery No No No No No
Smoking Yes (7,5 p-y) Yes (45 p-y) Yes (10 p-y) Yes (20 p-y) Yes (15 p-y)
Chemotherapy Cisplatin ×6 Cisplatin ×6 Cisplatin ×6 Cisplatin ×7 Cisplatin ×6
RT (pelvis) 45 Gy in 25 fx 45 Gy in 25 fx 45 Gy in 25 fx 45 Gy in 25 fx 45 Gy in 25 fx
Boost lymph nodes 5,4 Gy in 3 fx (pelvic) 5,4 Gy in 3 fx (pelvic) 0 Gy (No LN) 10 Gy (pelvic) 9 Gy in 5 fx (pelvic)
Brachytherapy 30 Gy in 5 tx 28 Gy in 4 tx 30 Gy in 5 tx 30 Gy in 5 tx 27,9 Gy in 4 tx
Date of last treatment 2008-07-23 2011-08-25 2010-12-23 2011-12-15 2012-04-16
RT Radiation therapy, Gy Gray, fx Fractions, tx Treatments, LN Lymph node, p-y Pack-years.
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at the cervical biopsy. Imaging was done, either a MRI or
a PET scan, to assess whether it was a recurrence or not. 2
patients had a PET scan exclusively, and 3 had a MRI and
a PET scan. MRI images for patient #1 at time of cervical
necrosis, and 3 months after, are shown in Figures 1 and
2. Treatment consisted of: counseling for smoking cessa-
tion for all patients, and vaginal douching. Metronidazole
was used in 3 patients. Opioid analgesics, hydromorphone
or morphine, were used to control the pain for 3 patients.
One patient has also received pregabalin and amitriptyline
for pain management.
All patients were assessed one month after the diagno-
sis of CN, and then, every 2 to 6 months. Median
follow-up until March 2013 was 19 months with a range
from 11 to 56 months, as shown in Table 3. Clinical im-
provement of the necrosis after the treatment was
assessed, and was positive in 4 patients (80%) at 1 month,
and in 1 patient at 4 months (20%). All patients had
complete resolution of the necrosis at 4 months. None
had stopped smoking permanently after the smokingTable 2 Brachytherapy dosimetry details: surface doses
to the colpostats in Gray
Fractions 1 2 3 4 5
Fx 1 R : 6.34 R : 8.64 R : 6.70 R : 9.01 R : 7.6
L: 6.36 L : 8.11 L : 6.82 L : 9.09 L : 12.9
Fx 2 R : 6.58 R : 8.29 R : 6.74 R : 8.39 R : 9.1
L : 6.57 L : 8.46 L : 6.74 L : 9.12 L : 11.7
Fx 3 R : 6.60 R : 8.41 R : 6.61 R : 10.79 R : 8.6
L : 6.63 L : 8.24 L : 6.61 L : 10.80 L : 9.7
Fx 4 R : 6.51 R : 8.36 R : 6.98 R : 9.79 R : 8.8
L : 6.58 L : 8.21 L : 7.06 L : 10.81 L : 9.8
Fx 5 R : 6.61 R : 6.65 R : 10.98
L : 6.52 L : 6.71 L : 10.92
Fx Fraction, R Right, L Left.cessation counseling, but 1 patient had stopped tempor-
arily for 3 months. Post-coital bleeding was evaluated in
each patient, and only one patient did not experience
this side effect. The bleeding lasted up to 1 month in 1
patient, up to 4 months in 1 patient, up to 1 year in 1
patient, and up to 2 years in the last patient. Finally, dis-
ease status was assessed in March 2013, and all the 5 pa-
tients were still alive with no clinical evidence of disease.
Discussion
Cervical necrosis after chemoradiation is a significant
complication. It reaches 1.75% of all women treated, and
2.76% of smokers who receive the same treatment mo-
dalities. Current knowledge of CN following RT for cer-
vical cancer is based on 5 case reports with a total of 12
patients. Our case series, the largest to date, evaluatesFigure 1 Patient #1: MRI at time of cervical necrosis
(January 2009).
Figure 2 Patient #1: MRI 3 months after treatment of cervical
necrosis (April 2009).
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Status in March 2013 Alive, NED Alive, NED
wk Weeks, mo Months, dx Diagnosis, MRI Magnetic resonance imaging, PET Positron
evidence of disease.
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smoking status impact on this complication.
Our data support the previously proposed theory that
smoking promotes this kind of complication, since it
limits the delivery of blood and oxygen to the body tis-
sues [15-17]. In our study, 100% of patients with CN
were smokers, while 63.51% of the whole cohort were
active smokers. This difference of more than 36% rein-
forces the idea that smoking is related to the risk of ne-
crosis. There might also be a correlation between the
number of pack-years of smoking and the time post-
radiation therapy before necrosis. In fact, the number of
pack-years of smoking could be a surrogate for long-
term poor tissue oxygenation, which, in turn, promotes
the necrosis of tissues. However, the majority of tobacco
smokers do not develop this complication, and our type
of study does not allow us to draw such conclusions, but
it would be interesting to assess this question in further
studies to identify potential predisposing factors.
Therapies used in this study include counseling for
smoking cessation, antibiotics such as metronidazole,
hydrogen peroxide vaginal douches, and use of opioids
such as hydromorphone and morphine. Smoking cessa-
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2013, should be strengthened. All the patients were
followed-up one month after the complication, and 4 out
of 5 had a clinical improvement at the visit, and the last
patient had a complete remission at the 4-month follow-
up. Phenomenal improvement was observed in as little
as 3 months after treatment, as shown in Figure 1 and
Figure 2. Unlike the case described by K.S. Matthews et al.,
conservative management of the cervical necrosis did not
fail, and has led to excellent results. This complication
should not be evaluated by laparoscopic examination, as
suggested by Marnitz et al., unless conservative treatment
has been tried. This exploration would have added an un-
necessary risk of complications, as well as surgical de-
bridement as proposed by Güth et al. Thus, a conservative
management is a safe and effective treatment for cervical
necrosis following radiation therapy, and such manage-
ment should be considered rather than a laparoscopic
examination and surgical intervention which are more in-
vasive and could result in chronic disability. Hyperbaric
oxygen therapy has been used for cervical cancer patients
with delayed radiation therapy damages, but was not ne-
cessary in the patients described in this study [18].
Given the retrospective nature of our study, a recall bias
may exist. Furthermore, some patients could have gone to
an outpatient clinic or to the emergency to manage the
cervical necrosis without being seen by the Radiation On-
cology Department, which might limit the generalizability
of our results for the percentage of CN after RT. However,
this study was conducted in a University Hospital Center
with a policy to send the patients to the belonging depart-
ment, and there is a close working relationship between
the radiation oncologists and the gynecologic oncologists
at the center. This case series was also performed at a sin-
gle care center, which provides a consistency in the care
and the management of the necrosis for the patients.
Conclusions
In conclusion, clinicians should be aware that a conser-
vative management for the treatment of cervical necrosis
in patients receiving radiation therapy for cervical cancer
is effective, and should be attempted. This complication
is more common in smokers, and cessation of tobacco
smoking should result in fewer complications of CN.
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